Abstract library

1886 results for "thymic neuroendocrine tumors".
#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors
Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang X, Li Y L, Shi Y F, Chen Y Y, ...
#258 Diagnosis and Management of Thymic Neuroendocrine Tumors: A Case Series Review
Introduction: Thymic neuroendocrine tumors (TNET) represent rare types of thymic tumors with an incidence of 0.01/100000 per year. They commonly show rapid disease progression and are rarely curable.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Christos Toumpanakis
#1318 MEN1 Associated Thymic Neuroendocrine Tumors in Oulu University Hospital Finland
Introduction: Thymic neuroendocrine tumors (TNET) are rare and account 2-5% of all thymic tumors. TNET can occur either sporadically or as a manifestation of an inherited tumor syndrome such as multiple endocrine neoplasia type 1 (MEN1). The prognosis is severe.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: M.D. Iina Yliaska
#449 Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report
Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Vita SarangaPerry
#237 Clinical Case of ACTH-secreting Thymic Carcinoma with Multiple Metastases to the Brain, Ovary and Skin
Introduction: ACTH-secreting thymic carcinoma (TC) is a rare neuroendocrine tumor which has a very aggressive course. We present a case of ACTH-producing TC in a 36-year-old woman.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs Irina Komerdus
#623 Measurement of Serum Chromogranin A Level in 56 Patients with Neuroendocrine Tumors Using Immunoradiometric Assay
Introduction: More NETs have been diagnosed with the increasing awareness of the diseases, but few centers in China have introduced CgA testing as a tumor marker.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: professor Huangying Tan
Authors: Tan H, Jia L, ...
#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients
Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Joanne De Laat
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#1918 Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour
Introduction: Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Miranda Stavrides-Eid
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.